Drug Profile
Linagliptin/pioglitazone - Boehringer Ingelheim
Alternative Names: Pioglitazone/linagliptinLatest Information Update: 24 Dec 2019
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Alkynes; Antihyperglycaemics; Piperidines; Purines; Quinazolines; Small molecules; Thiazolidinediones
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 24 Dec 2019 Discontinued - Phase-III for Type 2 diabetes mellitus in United Kingdom, USA, Latvia, Spain, Germany, Estonia (PO) (Boehringer Ingelheim website, December 2019)
- 29 Jan 2019 Chemical structure information added
- 15 May 2015 Linagliptin/pioglitazone is still in active development for Type-2 diabetes mellitus in USA, United Kingdom, Estonia, Germany, Latvia and Spain